APA (7th ed.) Citation

SH, P., MA, F., S, G., C, B., AW, Q., HH, L., . . . VB, S. (2020). Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat. Cardiovascular diabetology, 19(1), 19. https://doi.org/10.1186/s12933-020-00997-7

Chicago Style (17th ed.) Citation

SH, Park, et al. "Empagliflozin Improved Systolic Blood Pressure, Endothelial Dysfunction and Heart Remodeling in the Metabolic Syndrome ZSF1 Rat." Cardiovascular Diabetology 19, no. 1 (2020): 19. https://doi.org/10.1186/s12933-020-00997-7.

MLA (9th ed.) Citation

SH, Park, et al. "Empagliflozin Improved Systolic Blood Pressure, Endothelial Dysfunction and Heart Remodeling in the Metabolic Syndrome ZSF1 Rat." Cardiovascular Diabetology, vol. 19, no. 1, 2020, p. 19, https://doi.org/10.1186/s12933-020-00997-7.